The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-01 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
== Chemical structure == The chemical structure of sodium stibogluconate is somewhat ambiguous, and the structure shown above is idealized. Its solutions may contain multiple antimony compounds, although this heterogeneity may be unimportant. It has been speculated that the active species contains only a single antimony centre.
A 2017 systematic review and meta-analysis of suvorexant for the treatment of insomnia found that the medication significantly increased the rate of somnolence by 3.5-fold, daytime sleepiness/sedation by 3.1-fold, fatigue by 2.1-fold, abnormal dreams by 2.1-fold, and dry mouth by 2.0-fold. Conversely, suvorexant did not significantly differ from placebo in the rates of any other assessed adverse effects. This included back pain, diarrhea, dizziness, falls, headache, car accidents/traffic violations, nasopharyngitis, nausea, potential drug misuse, suicidal ideation, complex sleep behaviors, hypnagogic or hypnopompic hallucinations, and sleep paralysis. The overall risk of any adverse event was increased 1.07-fold while discontinuation due to adverse events was unchanged (RRTooltip relative risk=0.93, 95% CITooltip confidence interval 0.60 to 1.44). Tolerance, dependence, withdrawal, and rebound effects do not appear to occur with suvorexant in the treatment of insomnia at studied doses. In three-month clinical studies, no rebound insomnia as assessed by measures of sleep onset or maintenance was observed with discontinuation of suvorexant at doses of 15 to 40 mg. Similarly, no withdrawal effects were observed with discontinuation of suvorexant at these doses. However, in other reports, some tolerance as assessed by diminishing somnolence and rebound insomnia upon discontinuation has been noted. The orexin neuropeptides augment the signaling of the mesolimbic dopamine reward pathway and are thought to potentiate hedonic tone.
== Interpretation == The histological slides are examined under a microscope by a pathologist, a medically qualified specialist who has completed a recognised training program. This medical diagnosis is formulated as a pathology report describing the histological findings and the opinion of the pathologist. In the case of cancer, this represents the tissue diagnosis required for most treatment protocols. In the removal of cancer, the pathologist will indicate whether the surgical margin is cleared, or is involved (residual cancer is left behind). This is done using either the bread loafing or CCPDMA method of processing. Microscopic visual artifacts can potentially cause misdiagnosis of samples. Scanning of slides allows for various methods of digital pathology, including the application of artificial intelligence for interpretation. Following are examples of general features of suspicious findings that can be appreciated from low to high magnification on histopathology:
Sources: en.wikipedia.org
=== Metasoma === The metasoma (the "abdomen") of the ant houses important internal organs, including those of the reproductive, respiratory (tracheae), and excretory systems. Workers of many species have their egg-laying structures modified into stings that are used for subduing prey and defending their nests.
=== Small molecule CGRP antagonists (gepants) === Ubrogepant is approved for acute treatment of migraines Rimegepant (BMS-927711) is approved for acute migraine treatment (since February 2020) and for preventive treatment of episodic migraines (since May 2021). Atogepant (AGN-241689) is approved for preventative treatment of migraines Zavegepant (BHV- 3500) is a nasal spray approved for acute treatment of migraines. Telcagepant (MK-0974), reached phase III clinical trials; development discontinued in 2011. Olcegepant (BIBN-4096BS) is a drug candidate BI 44370 TA (BI 44370) MK-3207 SB-268262
Endometrium: the mucosa of the uterus Gastric mucosa Intestinal mucosa Nasal mucosa Olfactory mucosa Oral mucosa Penile mucosa Respiratory mucosa Vaginal mucosa Frenulum of tongue Anal canal Conjunctiva
With varying potencies ranging from high to low, it is a partial agonist of several of the serotonin 5-HT1 receptors, including the serotonin 5-HT1A, 5-HT1B, and 5-HT1D receptors, and is a partial agonist of the serotonin 5-HT2 receptors, including the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. The drug also interacts with α2-adrenergic receptors, with the sigma σ1 and σ2 receptors, with the imidazoline I1 receptor, and with other targets. Along with the preceding receptor interactions, MDMA is a potent partial agonist of the rodent trace amine-associated receptor 1 (TAAR1). Conversely however, due to species differences, it is far weaker in terms of potency as an agonist of the human TAAR1. The drug appears to act as a weak partial agonist of the human TAAR1 rather than as an efficacious agonist. In relation to the preceding findings, MDMA has been said to be essentially inactive as a human TAAR1 agonist. TAAR1 activation is thought to auto-inhibit and constrain the effects of amphetamines that possess TAAR1 agonism, for instance MDMA in rodents. Elevation of serotonin, norepinephrine, and dopamine levels by MDMA is believed to mediate most of the drug's effects, including its entactogenic, stimulant, euphoriant, hyperthermic, and sympathomimetic effects. The entactogenic effects of MDMA, including increased sociability, empathy, feelings of closeness, and reduced aggression, are thought to be mainly due to induction of serotonin release.
Sources: en.wikipedia.org
Wolverine's primary mutant power is an accelerated healing process, typically referred to as his mutant "healing factor", that regenerates damaged or destroyed tissues of his body far beyond that of normal humans. In addition to accelerated healing of physical traumas, Wolverine's healing factor makes him extraordinarily resistant to diseases, drugs and toxins. As a result of this ability, Wolverine has the appearance of a man in his early forties, although he is more than 100 years old. Wolverine's healing factor also affects a number of his physical attributes by increasing them to superhuman levels. His stamina is sufficiently heightened to the point that he can exert himself for hours. Wolverine's agility and reflexes are also enhanced to levels that are beyond the physical limits of the finest human athlete. Due to his healing factor's constant regenerative qualities, he can push his muscles beyond the limits of the human body without injury. Wolverine also has superhuman strength. The Muramasa blade, a katana of mystic origins that can inflict wounds that nullify superhuman healing factors, can suppress Wolverine's powers. Wolverine's senses of sight, smell, and hearing are super-humanly acute. He can see with perfect clarity at greater distances than an ordinary human, even in near-total darkness. His hearing is enhanced in a similar manner, allowing him to hear sounds ordinary humans cannot and hear across greater distances; he can hear the heartbeats of hostile living beings before conflict begins.
In an aqueous solution, precipitation is the "sedimentation of a solid material (a precipitate) from a liquid solution". The solid formed is called the precipitate. In case of an inorganic chemical reaction leading to precipitation, the chemical reagent causing the solid to form is called the precipitant. The liquid remaining above the precipitated or the centrifuged solid phase is also called the supernate or supernatant.
A December 2023 Gallup poll found a record low 28% of Americans reporting that they were satisfied with the way democracy is working in the country. In the weeks before the election, surveys showed that many favored a concession speech from the losing presidential candidate, had broad concerns about the state of democracy and were fearful of future acts of political violence. Surveys from the National Election Pool and VoteCast highlight the role the issue of democracy played in the election. According to results provided by the National Election Pool, 34% percent of voters said that the state of democracy mattered most to their vote. The poll found that 25% of those who cast a ballot said that democracy in the U.S. is secure, while 73% said it is threatened. VoteCast found that half of voters identified the future of democracy as the single most important factor for their vote. 9 in 10 Harris voters who said that democracy was the single most important factor expressed concern that electing Trump would bring the country closer to authoritarianism. About 80% of Trump voters who chose democracy as their top issue expressed concern about a Harris presidency becoming authoritarian.
== Directors == Lenton Parr, 1972–1984 (Victorian College of the Arts proclaimed 30 November 1972) Lionel Lawrence, 1985–1988 Alwynne Mackie, 1989–1995 Andrea Hull, 1995–2009 Su Baker, 2010–2017 Jon Cattapan, 2017–2020 Barbara Bolt, 2020–2021 Emma Redding, 2022–present
== External links == Magnesium at The Periodic Table of Videos (University of Nottingham) Chemistry in its element podcast (MP3) from the Royal Society of Chemistry's Chemistry World: Magnesium "Magnesium – a versatile and often overlooked element: New perspectives with a focus on chronic kidney disease". Clinical Kidney Journal. 5 (Suppl 1): NP. February 2012. doi:10.1093/ndtplus/sfs035. PMC 4455823. PMID 26069823. usgs.gov: Magnesium compounds and Magnesium Metal (Mineral Commodity Summaries 2025, p112-115)
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.